Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Following U.S. FDA Approval, Glenmark Plans Multi-Geography Launches For Crofelemer

This article was originally published in PharmAsia News

Executive Summary

India’s Glenmark has sped up its regulatory filings in a large set of countries, enthused by the prospects of filling unmet needs for HIV treatment regimens.


Related Content

Glenmark Steps Closer To First NCE With Positive Phase II Data For Crofelemer; Gears Up For Larger Trials
"We Have Gone Through Hardships But Our Passion Remains High," Says Glenn Saldanha, Managing Director, Glenmark Pharma: An Interview With PharmAsia News (Part 2 of 2)


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts